Core Points - The "Tongrentang Cup" vocational skills competition has commenced, highlighting the importance of traditional Chinese medicine craftsmanship [1] - The competition includes new categories for traditional Chinese medicine production, emphasizing the significance of these skills in modern times [3] - The increased difficulty of the competition challenges participants to demonstrate comprehensive skills across multiple traditional medicine production techniques [5] Group 1: Competition Overview - The event features 35 participants in traditional Chinese medicine production and 100 in medicine identification, with 35 and 18 advancing to practical preliminaries respectively [3] - The addition of traditional Chinese medicine production as a new category aims to enhance the development and transmission of traditional skills [3] Group 2: Participant Performance - Notable performances include Sun Xiaoguang from Yizhuang Factory, who excelled in the pill-making process, completing the initial step in just half an hour [7] - Zhang Ziwei from Daxing Factory demonstrated exceptional skill in slicing, producing uniform slices of Huangqi that met standards [9] - Du Zongru from Liujiayao Factory showcased her expertise in honey pill production, effectively controlling the heat during the critical refining stage [12] Group 3: Advancement in Competition - A total of 13 participants from the traditional medicine production category and 10 from the medicine identification category advanced to the semifinals [14]

Core Viewpoint - The integration of traditional Chinese medicine (TCM) and the food and beverage industry is gaining popularity, particularly among younger consumers, leading to a surge in innovative health products that combine TCM principles with modern dietary preferences [10][12][15]. Industry Trends - The market for TCM-infused food and beverages, such as herbal teas, medicinal pastries, and health-focused drinks, is expanding rapidly, with a notable increase in offerings from both traditional and new brands [10][11][15]. - The current trend shows a significant shift towards younger consumers, particularly those born after 1995, who are driving the growth in this sector [10][11]. Product Innovations - Various innovative products have emerged, including TCM-infused coffee, herbal teas, and health snacks, which are designed to appeal to health-conscious consumers [10][11][12]. - Hospitals and traditional medicine institutions are also entering the market with products like herbal bread and medicinal drinks, which are marketed for their health benefits [11][13][14]. Market Growth - The current market for ready-to-drink herbal beverages is projected to grow significantly, with estimates indicating that the number of outlets will double by the end of 2024 [15][16]. - The compound annual growth rate (CAGR) for the Chinese herbal beverage market is expected to exceed 88% over the next five years [16]. Cultural Significance - The concept of "food as medicine" is deeply rooted in Chinese culture, with historical texts emphasizing the health benefits of combining food and medicinal herbs [17][18]. - Recent regulations have clarified which TCM ingredients can be used in food products, promoting the safe integration of TCM into everyday diets [17][18]. Consumer Engagement - The rise of online platforms for purchasing TCM products has made it easier for consumers, particularly younger individuals, to access and try these health-oriented offerings [13][14]. - Educational initiatives and competitions are being organized to raise awareness about TCM and its applications in modern diets, encouraging more consumers to explore these options [20][21].

Group 1 - The company approved the acquisition of a 51% stake in Honghui Pharmaceutical Co., Ltd. for a total consideration of RMB 104.6372 million [2] - The acquisition agreement was initially signed with multiple parties, including Honghui Technology and Beijing Daopai Hongde Medical Investment Co., Ltd. [2] - Due to triggering audit clauses and profit fluctuation factors, the execution of the acquisition agreement was suspended, and the parties agreed to renegotiate the terms [3] Group 2 - The parties reached a consensus on the execution of the supplementary agreement, which includes the commitment from Honghui Pharmaceutical to change its name by July 31, 2025 [4] - Honghui Technology is required to refund the intention payment of RMB 52.3186 million to the company within five working days after signing the execution agreement [4] - The company will return the acquired 51% stake back to the original shareholder, Honghui Technology, after fulfilling the necessary approval procedures [4] Group 3 - The execution agreement confirms the specific execution of the acquisition and will not have a significant impact on the company's financial status or operating results [5] - The agreement is seen as beneficial for controlling investment risks and protecting the interests of all shareholders [5] - The company will continue to disclose information regarding the progress of this investment in accordance with relevant regulations [5]

证券代码：600085 证券简称：同仁堂 公告编号：2025-023 北京同仁堂股份有限公司 关于对外投资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 对外投资前期情况概述 北京同仁堂股份有限公司（以下简称公司或本公司）于 2024 年 10 月 29 日 召开第十届董事会第三次会议，审议通过了《关于北京同仁堂商业投资集团有限 公司对外投资的议案》，同意本公司之控股子公司北京同仁堂商业投资集团有限 公司（以下简称同仁堂商业）受让红惠（北京）科技有限公司（以下简称红惠科 技）持有的红惠医药有限公司（现更名为北京同仁堂宏德医药有限公司，以下简 称红惠医药）51%股权，转让价款为人民币 10,463.72 万元，具体内容详见公司 于 2024 年 10 月 30 日披露的《对外投资公告》（公告编号：2024-028）。 同仁堂商业与红惠科技、北京道培宏德医疗投资有限公司、红惠医药、王德 生及王爱晓（以下简称交易各方）共同签署了《关于红惠医药有限公司之股权转 让协议》（以下简称《股权转让协议》）。 公司签署对外投资 ...

1 二、对外投资进展情况 证券代码：600085 证券简称：同仁堂 公告编号：2025-023 北京同仁堂股份有限公司 关于对外投资的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资前期情况概述 北京同仁堂股份有限公司（以下简称公司或本公司）于 2024 年 10 月 29 日 召开第十届董事会第三次会议，审议通过了《关于北京同仁堂商业投资集团有限 公司对外投资的议案》，同意本公司之控股子公司北京同仁堂商业投资集团有限 公司（以下简称同仁堂商业）受让红惠（北京）科技有限公司（以下简称红惠科 技）持有的红惠医药有限公司（现更名为北京同仁堂宏德医药有限公司，以下简 称红惠医药）51%股权，转让价款为人民币 10,463.72 万元，具体内容详见公司 于 2024 年 10 月 30 日披露的《对外投资公告》（公告编号：2024-028）。 同仁堂商业与红惠科技、北京道培宏德医疗投资有限公司、红惠医药、王德 生及王爱晓（以下简称交易各方）共同签署了《关于红惠医药有限公司之股权转 让协议》（以下简称《股权转让协议 ...

金融界消息 截至2025年8月1日收盘，同仁堂（600085）报收于36.78元，上涨2.2%，换手率1.23%，成 交量16.91万手，成交金额6.22亿元。 天眼查商业履历信息显示，北京同仁堂股份有限公司，成立于1997年，位于北京市，是一家以从事医药 制造业为主的企业。企业注册资本137147.0262万人民币，实缴资本71930.85万人民币。公司法定代表人 为邸淑兵。 资金流向方面，今日主力资金净流入3864.77万元，占比成交额6.22%。其中，超大单净流入2937.82万 元、占成交额4.73%，大单净流入926.95万元、占成交额1.49%，中单净流出流出2172.72万元、占成交 额3.49%，小单净流出1692.05万元、占成交额2.72%。 同仁堂最新一期业绩显示，截至2025一季报，公司营业总收入52.76亿元、同比增长0.16%，归属净利润 5.82亿元，同比增长1.10%，扣非净利润5.81亿元，同比增长1.66%，流动比率3.450、速动比率1.943、 资产负债率32.65%。 通过天眼查大数据分析，北京同仁堂股份有限公司共对外投资了19家企业，参与招投标项目297次，知 识产 ...

金融界消息 截至2025年7月31日收盘，同仁堂（600085）报收于35.99元，下跌2.15%，换手率0.87%， 成交量11.98万手，成交金额4.34亿元。 资金流向方面，今日主力资金净流出2807.13万元，占比成交额6.47%。其中，超大单净流出1916.51万 元、占成交额4.42%，大单净流出890.61万元、占成交额2.05%，中单净流出流入2042.91万元、占成交 额4.71%，小单净流入764.21万元、占成交额1.76%。 同仁堂最新一期业绩显示，截至2025一季报，公司营业总收入52.76亿元、同比增长0.16%，归属净利润 5.82亿元，同比增长1.10%，扣非净利润5.81亿元，同比增长1.66%，流动比率3.450、速动比率1.943、 资产负债率32.65%。 天眼查商业履历信息显示，北京同仁堂股份有限公司，成立于1997年，位于北京市，是一家以从事医药 制造业为主的企业。企业注册资本137147.0262万人民币，实缴资本71930.85万人民币。公司法定代表人 为邸淑兵。 通过天眼查大数据分析，北京同仁堂股份有限公司共对外投资了19家企业，参与招投标项目297次，知 识 ...

Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange 300 Pharmaceutical Index has shown significant growth, with a 12.60% increase over the past month, 13.11% over the past three months, and 19.34% year-to-date [1] - The Shanghai Stock Exchange 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the Shanghai and Shenzhen 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the Shanghai Stock Exchange 300 Pharmaceutical Index include: Heng Rui Medicine (44.25%), Pian Zai Huang (9.6%), Yunnan Baiyao (7.98%), Kelun Pharmaceutical (6.66%), East China Pharmaceutical (6.13%), Fosun Pharmaceutical (5.62%), New Harmony (5.46%), Baillie Tianheng (4.07%), Tong Ren Tang (3.93%), and China Resources Sanjiu (3.33%) [1] - The market share of the index's holdings is 70.43% from the Shanghai Stock Exchange and 29.57% from the Shenzhen Stock Exchange [1] - The composition of the index by industry shows that drug formulations account for 66.73%, traditional Chinese medicine for 27.81%, and raw materials for 5.46% [1] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day following the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688766 | 普冉股 | 7.79 | 5.03 | 64.60 | 68.94 | 6.72 | | | 份 | | | | | | | 300679 | 电连技 术 | 8.00 | 4.36 | 47.49 | 50.50 | 6.34 | | 300045 | 华力创 | 6.25 | 8.30 | 20.24 | 21.25 | 4.99 | | | 通 | | | | | | | 600238 | *ST椰岛 | 4.93 | 3.25 | 7.03 | 7.23 | 2.85 | | 300761 | 立华股 | 2.54 | 0.92 | 19.35 | 19.79 | 2.29 | | | 份 | | | | | | | 000703 | 恒逸石 化 | 2.13 | 0.30 | 6.09 | 6.22 | 2.09 | | ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].